For example, patients with NSCLC with an anaplastic lymphoma kinase (ALK) gene rearrangement are more responsive to an ALK tyrosine kinase inhibitor (TKI), such as crizotinib, than to chemotherapy [2]. This evidence concerns the gene ALK and non-small cell lung carcinoma.